The clinical characteristics of our schizophrenia patients further support this notion, as most of them exhibited cognitive impairment along with reduced DAT availability, even with good clinical responses evidenced by PANSS scores (White et al., 2016). The gene discussed is SLC6A3; the disease is schizophrenia.